Parnell Pharmaceuticals Holdings Ltd. announced financial results for the full year ended 31 December 2018. For the year, the company reported revenue growth of 39% over the full year in 2017 to $26.5 million and Net Profit After Tax of $0.1 million, an improvement of $23.3 million over a full year loss of $23.1 million in 2017.

For the year 2019, the company's expects full year revenue guidance to be of $31.0 to $33.0 million. This guidance represents a 17% to 25% increase in revenues.